z-logo
open-access-imgOpen Access
Determination of Clinical Utility of Novel Biochemical Markers in Osteoarthritis
Author(s) -
Ankita Kondhalkar,
Ranjit Ambad,
Neha Bhatt,
Roshan Kumar Jha
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i39a32166
Subject(s) - osteoarthritis , medicine , joint capsule , osteopontin , synovial fluid , cartilage , inflammation , knee joint , endoglin , joint disease , pathology , surgery , genetics , alternative medicine , stem cell , biology , cd34 , anatomy
Osteoarthritis is a progressive joint disease characterized by loss of articular cartilage, joint bone hypertrophy, subchondral sclerosis, and chemical and morphological alterations in the synovial membrane and joint capsule. Stiffness, soreness, and focused dislocation of the articular cartilage are changes in the disease seen at the last level of OA, as well as synovial inflammation. Pain is a common clinical symptom, especially after prolonged exercise and weight bearing, and stiffness occurs after inactivity. Biologic markers will also play an important role in the production and monitoring of new structure-modifying therapies for osteoarthritis due to their rapid changes in response to treatment. Aim: We conducted an observational study to estimate biochemical markers in the knee osteoarthritis patients who came to SMHRC Nagpur for a routine visit. Material and Methods: The study included 60 people who visited Shalinitai Meghe hospital in Nagpur for a health check-up. We were able to keep the two groups apart here. The control group is comprises of Healthy Volunteer, while the study group is made up Knee osteoarthritis patients. Each community consists of 30 patients. COMP, Endoglin, Osteopontin, Hs-CRP: all of these parameters were estimated by commercially available ELISA kit. Results: The levels of COMP, Endoglin, Osteopontin, and Hs-CRP in the study group were significantly higher than in the control group. In synovial fluid detection, endoglin levels in the sample group are not significantly higher than in the control group. Endoglin levels in the blood increase, as do other parameters. Conclusion: These findings show a significant increase in the systematic and local development of these biomarkers in the main OA of the knee, as well as the link between disease severity and its production, meaning that they may be involved in OA pathogenesis. Longitudinal studies with repetitive measurements of these biomarkers in plasma and synovial fluid and their interactions with knee pain OA are necessary to track or predict the clinical course of OA and, ultimately, determine their potential role in determining the best time to participate.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here